Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

Conditions

• Pancreatic Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• bevacizumab — BIOLOGICAL
• gemcitabine hydrochloride — DRUG
• oxaliplatin — DRUG

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with gemcitabine and oxaliplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with gemcitabine and oxaliplatin works in treating patients with metastatic pancreatic cancer.

Key Dates

First listed

Jun 3, 2005

Start date

Jun 30, 2005

Status verified

Dec 2016

Primary completion

Aug 31, 2006

Completion

Nov 30, 2010

Study Design

Enrollment

53 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: gemcitabine + bevacizumab + oxaliplatin
  Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR. After completion of study treatment, patients are followed every 3-6 months for up to 5 years.

Primary Outcome Measure

Survival at 6 months [ Time Frame: at 6 months ]

Locations (201)

Find similar trials in Mobile, AL

Related Studies

• Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
  Recruiting · Mayo Clinic · Phoenix, Arizona
• Pancreatic Adenocarcinoma Gene Environment Risk Study
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
  Recruiting · Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania